Brief: Gossamer Bio Q2 EPS USD 0.22
12/08/2024 21:01
Aug 12 (Reuters) - Gossamer Bio Q2 basic EPS USD 0.22. * Q2 operating expenses USD 43.755 million * Q2 operating income USD 52.087 million * Q2 net income USD 49.232 million
Recent news on Gossamer Bio
See all newsBrief: Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gossamer Bio - Board Approves Amendment And Restatement Of Bylaws Effective Sept 3, 2026 - SEC Filing